

Date: March 31, 2025

Ref. No.: KDL/SE/146/2024-25

To,

BSE Limited

Corporate Relationship Department

25th Floor, Phiroze Jeejeebhoy Towers

Dalal Street, Mumbai- 400001

Scrip Code: 543328

To,

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East)

Mumbai – 400051

NSE Symbol: KRSNAA

Dear Sir/Madam,

Subject: Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for acquisition of 23.53% stake in equity shares of Apulki Healthcare Private Limited.

In continuation to the Company's intimation dated September 25, 2024 vide reference number KDL/SE/083/2024-25 and pursuant to Regulation 30 read with Schedule II, Part A, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Company has entered into a Share Purchase and Share Subscription Agreement ("SPSS") and a Shareholders Agreement ("SHA") on March 31, 2025 with Apulki Healthcare Private Limited ("AHPL") to acquire 23.53% equity shares in AHPL.

In this regard, please find enclosed herewith, disclosure containing the details pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09 September 2015 as Annexure I.

You are requested to take the above information on your record.

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose Company Secretary and Compliance Officer







Annexure I

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are given below:

Sr No	Particulars	Details	
1	Name of the target entity, details in brief such as size, turnover etc.;	Name: Apulki Healthcare Private Limited ("Investee Company")	
		Authorized Capital	25,00,000
		Paid Up Capital	1,00,000
		Turnover	Nil
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No, the transaction will not fall within the related party transaction and none of the promoter/promoter group/group companies are interested in the entity with whom the agreements are executed.	
3	Industry to which the entity being acquired belongs;	The Investee Company is engaged in establishing, operating and maintaining hospitals, focusing on oncology and cardiology	
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The Investee Company is engaged in establishing, operating and maintaining hospitals, focusing on oncology and cardiology in the public private partnership mode having entered into agreements for a tenure of 30 years. Krsnaa Diagnostics Limited gets exclusive partnership of operating and maintaining diagnostic services of the Investee Company's hospitals.	
5	Brief details of any governmental or regulatory approvals required for the acquisition;	None	sspriais.
6	Indicative time period for completion of the acquisition;	NA	
7	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration.	
8	Cost of acquisition or the price at which the shares are acquired;	Cost of Acquisition for 23.53% equity shares in Investee Company is INR 31.25 Crore	
9	Percentage of shareholding/ control acquired and / or number of shares acquired;	23.53% of shareholdin	

Krsnaa Diagnostics Ltd.



10	Brief background about the entity acquired	The Investee Company is engaged in	
	in terms of products/line of business	establishing, operating and maintaining	
	acquired, date of incorporation, history of	hospitals, focusing on oncology and	
	last 3 years turnover, country in which the	cardiology.	
	acquired entity has presence and any other		
	significant information (in brief);	The Investee Company is formed in	
		compliance with the terms for executing	
		the Cancer and Cardiac care Project.	
		Date of Incorporation: June 13, 2022	
		Turnover: Nil	
		Turnover. IVII	

Krsnaa Diagnostics Ltd.

S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India) 020 27402400 | info@krsnaa.in

